Nuvectis Pharma (NVCT) Interest Expenses (2021 - 2026)

Nuvectis Pharma (NVCT) has 6 years of Interest Expenses data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 39.36% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (down 39.36% YoY), and the FY2025 full-year result was $1.0 million, down 94.72% from the prior year.
• Interest Expenses improved to $1.1 million in Q1 2026, from $1.0 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $19.5 million in Q4 2024 to a low of $498000.0 in Q3 2025.
• A 5-year average of $5.6 million and a median of $2.8 million in 2022 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses soared 1095.54% in 2023 and tumbled 95.18% in 2024, its largest moves.
• Tracing NVCT's Interest Expenses over 5 years: stood at $8.6 million in 2022, then jumped by 69.03% to $14.5 million in 2023, then soared by 34.76% to $19.5 million in 2024, then plunged by 94.72% to $1.0 million in 2025, then climbed by 6.11% to $1.1 million in 2026.
• Business Quant data shows NVCT's Interest Expenses at $1.1 million in Q1 2026, $1.0 million in Q4 2025, and $498000.0 in Q3 2025.